Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial - PubMed
3 days ago
- #rectal cancer
- #neoadjuvant therapy
- #clinical trial
- The CONVERT trial compared neoadjuvant chemotherapy (CAPOX) versus chemoradiation (nCRT) in locally advanced rectal cancer (LARC) with uninvolved mesorectal fascia (MRF).
- Primary endpoint was 3-year locoregional recurrence-free survival (LRRFS), with results showing 97.4% for nCRT and 96.3% for nCT (HR 1.40, 95% CI 0.53-3.68).
- Secondary endpoints included 3-year disease-free survival (DFS) and overall survival (OS), which were similar between groups (DFS: 89.2% vs. 87.9%; OS: 95.0% vs. 94.1%).
- The nCT group had fewer grade 2-4 long-term adverse events (16.0% vs. 26.3%) and lower proctitis rates (33.6% vs. 41.7%) compared to nCRT.
- Non-inferiority of nCT was not confirmed due to very low recurrence rates in both groups, but nCT showed comparable efficacy with reduced toxicity.